Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990. by Raina, V. et al.
Br. J. Cancer (1993), 67, 573-577
Clinical profile and problems of management of 108 cases of germ cell
tumours of testis at Institute Rotary Cancer Hospital, All India Institute
of Medical Sciences New Delhi 1985-1990
V. Raina, N.K. Shukla, G.K. Rath, N.P. Gupta, M.C. Mishra, T.K. Chaterjee &
A.K. Kripalani
Institute Rotary Cancer Hospital, All India Institute ofMedical Sciences, Ansari Nagar, New Delhi 110 029, India.
Summary A retrospective analysis of 108 cases of primary germ cell tumours of testis seen over a 6 year
period at Institute Rotary Cancer Hospital of All India Institute of Medical Sciences, New Delhi is presented.
There were 45 (42%) cases of seminoma and 63 (48%) of non-seminomatous germ cell tumours (NSGCT).
The median age at presentation was 35 and 30 years respectively. Almost half (56) patients presented in
advanced stage (stages lIc-IV). Tumours in undescended testis formed an important subgroup (14%). The
standard approach of treatment was radiotherapy in stages I & II seminomas and chemotherapy in bulky
seminomas and metastatic NSGCT. Chemotherapy protocols used were VAB-6 and PVB. Although a policy
of surveillance has been practised for stage I NSGCT, it is debatable whether it is universally suitable for our
patients. The results of treatment in low volume disease are comparable to that in the west but the
management of bulky disease requires a more aggressive approach. Unfortunately only 74 out of 108 (68.5%)
patients were able to complete the treatment prescribed. Most of the defaulters were from the chemotherapy
group because of inability to afford the drugs. The probability of survival of those who completed treatment
was 0.77 at 4 years. Since testicular tumours are largely curable, a more vigorous policy ofdetection, follow up
and treatment needs to be pursued. Better screening of children with undescended testis will reduce cancer in
this group. Failure to provide chemotherapy to all patients is particularly unfortunate for a curable disease
like testis cancer.
Testicular tumours account for only about 1% of all cancers
but are the most common neoplasms in the 15-35 year old
age group (Einhorn et al., 1977). This cancer thus has the
potential of resulting in the loss of productive years of life.
With the advent of modern chemotherapeutic agents most
importantly DDP, testicular cancers have become largely
curable. Although the natural history of this neoplasm is well
known in the west, its natural history in India which cur-
rently has a population of about 850 million is not well
documented. The aim of this paper is to put on record the
clinical features, treatment and problems of management of
108 cases of primary germ cell tumours of testis that were
seen over a 6 year period at Institute Rotary Cancer Hospital
(IRCH) of All India Institute of Medical Sciences (AIIMS)
New Delhi. This is a regional cancer centre and gets referrals
from north and north central India involving 50 million, a
population almost equal to that of UK.
Materials and methods
Case records of all patients with testicular tumours that were
registered at IRCH between Jan 1985 and Dec 1990 were
analysed. These patients had a proven histological diagnosis,
a complete clinical examination and staging. One hundred
and thirteen cases of primary testicular tumours were
registered. Five of these patients had non germ cell tumours
and have been excluded from analysis. Besides clinical
examination, all patients had complete hemogram, routine
biochemistry, markers like b-human chorionic gonadotrophin
and alpha fetoprotein, radiograph of the chest, and CT
scans. Patients were staged using the Royal Marsden Hos-
pital classification (Peckham et al., 1979). Histological stag-
ing was done using the WHO classification (Mostofi & Sobin,
1977). Probability of survival was calculated in those patients
who had completed the planned treatment.
Seminomas
There were 45 cases of seminoma. These presented at a
median age of 35 years (range 19-74 years). There were
proportionately more cases in early stages i.e. 28 out of 36
(stages I-IIb).
NSGCT
There were 63 cases in this category. The commonest in this
group was immature teratoma in 52 (82%) cases. The median
age of these tumours was 30 years with a range of 3-50
years. NSGCT were distributed more or less evenly with
respect to stages.
Undescended orpartially descended testis
There were 15 cases in this category accounting for 14% of
all cases of primary genn cell tumours of testis. Ten patients
had unilateral and five bilateral abnormalities of descent. All
these patients had either abdominal swelling or pain as the
presenting feature and had large abdominal masses or ascites.
Extrapolating the Royal Marsden Hospital classification, all
patients in this category were in either stage Ilc or Ild. The
median age of these patients was 29 years with a range of
20-43 years. Six patients had seminoma and nine
NSGCT.
Mode ofpresentation
In 74 (71%) patients the duration of symptoms was more
than six months. An analysis of the mode of presentation
revealed testicular swelling to be the feature in 70 (65%)
cases. The second commonest mode of presentation was
abdominal swelling i.e. in 28 cases (25%). The other ten
patients had supraclavicular node (five), pulmonary (three),
neurological (one), skeletal (one) metastasis as the presenting
features. The distribution of staging with reference to his-
tological type is shown in Table I. It is obvious from the
table that almost half (56) patients were in advanced stage,
i.e. stages IIc-IV. All patients had CT scanning, hence
understaging was unlikely. Exact staging was not known in
seven cases because of incomplete information. Of the 27
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Table I Stages and histology of testicular tumours at IRCH
Stage Seminoma NSGCT Overall
I 20 12 32
II 8 14 22
III 2 3 5
IV 6 21 27
Incomplete staging 3 4 7
Undescended 6 9 15
Total 45 63 108
Treatment completed 35 39 74 (68.5%)
patients with stage IV disease six had pulmonary, 13 hepatic,
eight with both hepatic and pulmonary metastasis.
Treatment strategies and results
All 93 patients who had normally situated testis had
orchidectomy. In 81 patients this was a high inguinal
orchidectomy done either by the referring surgeon or at our
hospital. In others scrotal orchidectomy was done in
peripheral hospitals and patients were referred thereafter. Of
the 15 patients with abnormalities of descent 14 had under-
gone laparotomy for purposes of histological diagnosis and
treatment. In one patient the diagnosis was made on a trucut
biopsy of the abdominal mass.
Seminoma
There were 19 cases of stage I seminoma. These were treated
by conventional radiotherapy involving two anterior and
posterior portals encompassing bilateral para-aortic and pel-
vic lymph nodes delivering a dose of 30 Gy in 4 weeks with
cobalt 60 beam. The scrotum and inguinal lymph nodes were
included in treatment portals in patients having extracapsular
spread or in patients with a previous history of surgery in the
inguinoscrotal region. Nine patients who came from distant
regions were lost to follow up at variable periods after com-
pleting radiotherapy. Ten patients continue to have no
evidence of disease at a median fiollow up of 18 months
(range 12-76 months). There were 26 cases of stages II-IV
seminoma (including five with abnormalities of descent and
three with incomplete information on staging). Six patients
who had non-bulky disease (IIA & IIB) were treated with
radiotherapy and 20 patients with bulky or advanced disease
started on primary chemotherapy, 12 on VAB-6 and eight on
PVB protocols (Vugrin et al., 1981 and Einhorn & Donohue,
1977). Ten patients did not complete their treatment (six
radiotherapy and four chemotherapy) due to expenses in-
volved and returned to their native places. Of the 16 patients
who completed their prescribed chemotherapy 12 achieved
complete remission and are disease free at a median of 18
months (range 12-60 months). Four patients died of pro-
gressive disease. The probability of survival in 35 patients
who completed their treatment is shown in Figures 1 and 2.
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Figure 1 Probability of survival seminoma (stages II-IV) 16 pts.
1.0 ?
0.8
0.7 [
0.6
co
.0
0
0-
0.5 [
0.4 [
0.3
0.2 [
0.1
A
Survival in months
Figure 2 Probability of survival seminoma all stages (35 pts).
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NSGCT
There were 12 cases of stage I NSGCT. Ten patients were
put on surveillance. Six patients continue to be disease free at
a median of 12 months (range 10-56 months). One patient
relapsed at 9 months. This relapse was detected on periodic
marker estimation. Patient was given three courses of BEP
(Bleomycin, Etoposide and DDP) chemotherapy and promp-
tly went into remission. Three patients have been lost to
follow up. One patient was treated by pelvic radiotherapy
and is alive and disease free at 30 months. Another under-
went retroperitoneal lymph node dissection (RPLND), was
found to be disease free and continues to be so at 36 months.
There were 51 cases of advanced NSGCT (stages II-IV
including nine with abnormalities of descent and four with
incomplete information on staging). Only 27 of these patients
completed their chemotherapy. Others either declined
chemotherapy or dropped out after having one or two
courses. Twenty-one (77%) of 27 patients went into complete
remission. Of these 17 achieved complete remission that was
achieved with chemotherapy alone. In four patients partial
remission that was ahieved with chemotherapy was converted
into complete remission by resection of residual tumour in
the abdomen. The median follow up of these patients is 18
months with a range of 8-60 months. One patient died due
to chemotherapy toxicity and two died ofprogressive disease.
Three patients achieved only partial remission. They had
significant residual disease at multiple sites, were not con-
sidered suitable for resection and died in spite of salvage
chemotherapy. The probability of survival in those who com-
pleted treatment is shown in Figures 3 and 4.
Two different chemotherapy protocols were used. These
were PVB (DDP, Vinblastine, Bleomycin) and VAB-6 (DDP,
Vinblastine, Actinomycin-D, Bleomycin, Cyclophosphamide).
A total of 62 patients of either seminoma or NSGCT were
started on chemotherapy. Of these 17 patients did not com-
plete chemotherapy and are not evaluable with regard to
response. The major reason was the cost of chemotherapy.
Although the state health services and IRCH are aimed to
provide free treatment to all patients, it has actually not been
possible to do so because of the cost of anti-cancer drugs,
most of which are still imported. Patients who can afford are
asked to buy their own drugs while as state funding or
voluntary agency support is available for funding of the
treatment of poor patients. This is not adequate for the most
poor many of whom return home after becoming relatively
symptom free after receiving one or two courses of
chemotherapy. They do not respond or come back for treat-
ment even after they are sent reminders. It is also frequently
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Figure 3 Probability of survival NSGCT (stages II-IV) 27 pts.
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Figure 4 Probability of survival NSGCT all stages (39 pts).
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observed that the some of the poorest patients who are
offered all chemotherapy free by voluntary agencies or from
hospital are unable to complete their treatment either because
they are not able to stay in Delhi due to pressing problems at
home or do not understand the often difficult advice about
chemotherapy and its toxicity because of almost nil educa-
tion. Occasionally patients have no choice but to return
home because all of them cannot be accomodated in the
inpatient wards and are treated in day care instead. It is
therefore unfortunate that only 74 out of 108 (68%)
registered patients were able to complete their treatment.
There were no deaths in stage I in either group. Some
patients stopped coming for follow up even after completing
their treatment. We therefore calculated the probability of
survival. The data for the group as a whole is provided in
Figure 5. Median survival was not attained in any group.
The aim of showing the various probability of survival curves
which have been estimated by Kaplan-Meier method is not
to either compare the groups or to demonstrate the prognos-
tic factors but to show the results in various groups of
patients in the background of our working conditions. The
number of patients at risk at various time periods have been
provided in the figures and gives a fair idea of the loss of
follow up.
Discussion
As a result of remarkable advances in chemotherapy of
testicular cancer it is obvious that this malignancy has
become important to detect and treat. Testicular tumours
though prevalant in the most productive years of the life are
relatively uncommon. It is therefore difficult for one centre to
have a large experience. Review of literature has revealed
paucity of information on the pattern and management of
testicular cancer in India. The report of 200 cases of tes-
ticular cancer from Post Graduate Institute of Medical
Education and Research (PGIMER) Chandigarh, to our
knowledge is the only major publication on this subject from
India (Grover et al., 1985). Testicular tumours form about
1% of all tumours registered at IRCH. Population surveys
indicate a crude incidence rate of 0.7 to 1 per 100,000
persons at Banglore, Bombay and Madras, the three centres
from where information is available (Annual Report 1987,
National Cancer Registry Programme, New Delhi). As
population surveys from the rest of the country are not
available the exact incidence of this disease is not known.
Based on the rates of incidence from other major cities in
India, it was expected that at least 350 new cases would be
diagnosed every year. For the last 2 years i.e. 1990 and 1991
we have been registering about 60 cases every year which is
slightly less than 20% of all possible new cases occurring in
the population. It is obvious that all patients are not seen at
our center. This could be either because they are not diag-
nosed or receive treatment in district hospitals or may be
having self referrals to other major cancer centres in Bombay
etc. It is also possible that many patients do not seek treat-
ment. Notwithstanding all this, our is the largest referral
centre for the population involved. It is interesting to note
that almost three times as many (1000) new cases of germ cell
tumour of testis are reported from UK every year, a popula-
tion of 50 million, approximately the same as under discus-
sion. Median age of our patients with seminoma is a decade
lower than the reported western figures (Einhorn et al.,
1977). The reasons for this are not clear but could be because
older patients from distant places find it difficult to attend a
tertiary hospital like ours and may be receiving treatment
locally. The shorter life expectancy in India could also effect
the age distribution of this condition. The lag period from
symptoms to actual diagnosis is long i.e. more than 6 months
in 70% cases. This is because of tendency to not to report
symptoms involving a private organ and sparse availability of
health care in certain areas. Quite often the only symptom is
swelling, the condition is misdiagnosed as hydrocoele, and
the patient reassured till testicular or abdominal pain or
abdominal mass point to malignancy. This in turn results in
patients being diagnosed in an advanced state. A look at our
table indicates that only about a third (35) ofpatients were in
stage I-IIb. This has an important bearing on the long term
prognosis. Many studies have shown that high volume
disease is the most important indicator of poor prognosis
(Peckham et al., 1979). Tumours in undescended testis
formed a proportion that is much higher than the current
western figures and reflects the underdeveloped health ser-
vices in peripheral areas (Einhorn et al., 1979). All patients
who had tumours on undescended or maldescended testis
had received either no or very poor primary education and
belonged to very poor socio-economic class. Majority of such
cases underwent laparotomy for diagnosis (14 out of 15).
Resection in most of these cases was incomplete and patients
required either chemotherapy or radiotherapy. This practice
has changed over the last 2 years. Whenever this condition is
suspected now (any abdominal mass with absent scrotal
testes) tumour markers i.e. B-HCG and AFP are done, and
histopathology obtained by tru-cut needle. If germ cell
tumour is diagnosed, the patient is given appropriate
chemotherapy and surgery reserved only for resistant residual
masses or removal of intraabdominal testis.
With the availability of reliable markers and investigation
facilities like whole body CT scanning and ultrasound the
management of testicular tumours has become more rational
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Figure 5 Probability of survival all testicular cancer (74 pts).
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in terms of early diagnosis, appropriate staging and better
monitoring ofpatient's response to treatment. The number of
patients receiving chemotherapy in each subgroup was small.
Of the 74 patients who completed the planned treatment the
probability of survival at 4 years was 0.77. This figure com-
pares favourably with most western figures (Graham et al.,
1988). Since there have been no deaths in stage I in either
group, the survival figures for advanced disease are likely to
be worse. It is exactly these patients in whom a more aggres-
sive treatment is required. It may appear that our response
and survival results are not much inferior to western figures.
We suggest that our figures be taken with caution because of
high drop out rates of patients who did not complete their
treatment. A majority of these patients had advanced or
bulky disease.
Our main problems remain the (i) management of bulky
disease, (ii) inability of patients to take complete treatment
(iii) loss of follow up even in those who have become asymp-
tomatic after initial treatment or have completed the pre-
scribed treatment. This is particularly unfortunate for a
potentially curable cancer like that of testis. The reasons are
poverty, low education of patients and distances that they
have to travel to because of the paucity of good cancer
centres. The inability to take complete treatment is parti-
cularly great for patients with stage II bulky, III & IV. This
is obviously because of the vast majority require chemo-
therapy which is expensive. Some of these patients return
home without even informing us. We attempted to contact
these patients by means of reply paid letters but the response
was only 36%. This situation needs to be improved because
testicular tumour patients are curable even in advanced stage.
Our policy in stage I NSGCT is surveillance. This however
may not be universally appropriate for our conditions, as
surveillance presumes that the follow up be strict. Three of
our patients on surveillance were lost to follow up. Also the
cost of surveillance may be prohibitive in terms of frequent
visits to hospital and need for regular CT scanning. CT scan
and ultrasound facilities are available only in major hospitals
in the cities. In such patients where it is feared that follow up
may not be adequate, giving adjuvant chemotherapy or
radiotherapy may be a good alternate option. This approach
may be wholly appropriate for a certain section of our
population and is currently being debated in our department.
We do not currently favour retroperitoneal lymph node
dissection for stage I NSGCT partly because of its significant
morbidity in terms of failure of ejaculation which can
become a major problem in young sexually active males and
partly because it is difficult to convince asymptomatic
patients to undergo major surgery. The current policy is to
stratify patients into low, intermediate and high volume
disease and to offer chemotherapy appropriate to the stage
and volume as is practised by EORTC.
We thank Dr K.R. Sundaram PhD, Additional Professor of Bio-
statistics AIIMS for statistical advice, Mr Kailash of Computer
Facility for computer assistance and Dr V. Raina who undertook the
word processing himself.
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